Brief: Synlab Publishes Joint Statement On Cinven Offer

Synlab AG

02/11/2023 16:55

Nov 2 (Reuters) - SYNLAB AG  SYAB.DE :
    * PUBLISHES JOINT REASONED STATEMENT ON PUBLIC ACQUISITION
OFFER
BY CINVEN
    * MANAGEMENT BOARD AND SUPERVISORY BOARD OF SYNLAB AG
PUBLISHED
THEIR JOINT REASONED STATEMENT, IN WHICH THEY MAKE A NEUTRAL
STATEMENT
    * BOARDS ABSTAIN FROM A RECOMMENDATION TO SYNLAB
SHAREHOLDERS
WHETHER TO ACCEPT OR DECLINE OFFER.
    * MANAGEMENT BOARD AND SUPERVISORY BOARD CONCLUDED THAT
OFFER
PRICE OF EUR 10.00 PER SYNLAB SHARE DOES NOT REFLECT LONG-TERM
VALUE OF COMPANY
    * SAYS HOWEVER, OFFER PRICE GIVES SHORT-TERM ORIENTED OR
RISK-AVERSE SHAREHOLDERS POSSIBILITY OF A SECURE AND TIMELY
VALUE REALISATION.
    * BOARDS RATE POSITIVELY CINVEN'S COMMITMENT TO FURTHER
STRENGTHEN
SYNLAB BUSINESS STRATEGY, WHICH IS AIMED AT CUSTOMER CENTRIC
MEDICAL EXCELLENCE LEADING TO A SUSTAINABLE AND PROFITABLE
GROWTH TRAJECTORY.
    * ALL MEMBERS OF MANAGEMENT AND SUPERVISORY BOARDS HAVE
DECLARED
TO TENDER ALL SYNLAB SHARES THEY MAY HOLD; DR BARTHOLOMÄUS
WIMMER WILL SELL 60% OF HIS SHARES IN OFFER AND RE-INVEST
REMAINING SHARES.

Source text for Eikon:  ID:nEQ6pRWLpa 
Further company coverage:  SYAB.DE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))